68 out of 93
All are true regarding selective estrogen receptor down-regulator (SERD), Fulvestrant except (LQ)
|A||Used for treatment of advanced breast cancer|
|B||Is a selective estrogen antagonist|
|C||Is slower and short acting and less safer than SERMs|
|D||Administered as once a month i.m. dose|
Ans. C Is slower and short acting and less safer than SERMs
- Fulvestrant is selective estrogen-receptor downregulators (SERD), having an improved safety profile, faster onset, and longer duration of action than the SERMs due to its pure ER antagonist activity.
- Fulvestrant was approved for postmenopausal women with hormone receptor-positive metastatic breast cancer that has progressed despite antiestrogen therapy.
- Fulvestrant is administered intramuscularly at monthly intervals and well tolerated with the most common adverse events being nausea, asthenia, pain, vasodilation (hot flushes), and headache.